RT @doctorRBC: About to get my learnin' on! #RNL2023 @RheumNow
Tweet Content
About to get my learnin' on! #RNL2023 @RheumNow
RT @uptoTate: #RNL2023 is up and running! Join us online! @RheumNow https://t.co/AGbpEjXSh6
Tweet Content
#RNL2023 is up and running! Join us online! @RheumNow https://t.co/AGbpEjXSh6
RT @ericdeinmd: Follow me today and tomorrow for @RheumNow Live 2023 Coverage! #RheumTwitter #RNL2023 https://t.co/sS6Ao
Tweet Content
Follow me today and tomorrow for @RheumNow Live 2023 Coverage!
#RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij
QD Clinic - RheumNow Live 2023 Preview https://t.c
Tweet Content
QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY
Links
A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 in
Tweet Content
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/sax8iHuljb https://t.co/71zqAzZViV
Links
Itaconate - A Potential New Immunosuppressive Researchers have revealed the modulatory effect of the anti-inflammatory
Tweet Content
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM
Links
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023
Tweet Content
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023
RT @ericdeinmd: Follow my coverage tomorrow and Sunday! #RNL2023 RheumNow Live â¦@RheumNowâ© #RheumTwitter https://t.c
Tweet Content
Follow my coverage tomorrow and Sunday!
#RNL2023 RheumNow Live
@RheumNow #RheumTwitter https://t.co/6cZHJxPltA
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroi
Tweet Content
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroids, 16%IVIG alone, 4% steroids alone. Anakinra gave no short-term CV benefits over IVIG and glucocorticoids alone. https://t.co/IVaC5dXzs8
Links
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ S
Tweet Content
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx
Links
